EOLS Evolus, Inc.
Nasdaq · SEC CIK 1570562 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $1.84M 7 sales by 2 insiders
- Filings on record
- 146 since 2021-08-12, latest 2026-09-04 19:04
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| MOATAZEDI DAVID | See Remarks, Dir | — | $1.66M |
| Avelar Rui | See Remarks | — | $177.7K |
| Mitchell Tatjana | CFO | — | — |
| Stewart Brady | Dir | — | — |
| Malik Vikram | Dir | — | — |
| Parschauer Karah Herdman | Dir | — | — |
| White Albert G III | Dir | — | — |
| GILL DAVID N | Dir | — | — |
Transactions 158
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-31 | 2023-01-27 | EOLS | FARRELL PETER C | Dir | A - Grant | $0.00 | +8,293 | 43.2K | +24% | $0 |
| D | 2023-01-31 | 2023-01-27 | EOLS | GILL DAVID N | Dir | A - Grant | $0.00 | +8,293 | 37.9K | +28% | $0 |
| D | 2023-01-31 | 2023-01-27 | EOLS | Stewart Brady | Dir | A - Grant | $0.00 | +8,293 | 44.8K | +23% | $0 |
| D | 2023-01-31 | 2023-01-27 | EOLS | HAYMAN ROBERT | Dir | A - Grant | $0.00 | +8,293 | 48.2K | +21% | $0 |
| D | 2023-01-31 | 2023-01-27 | EOLS | Malik Vikram | Dir | A - Grant | $0.00 | +8,293 | 77.6K | +12% | $0 |
| D | 2023-01-31 | 2023-01-27 | EOLS | Parschauer Karah Herdman | Dir | A - Grant | $0.00 | +8,293 | 43.2K | +24% | $0 |
| D | 2023-01-27 | 2023-01-25 | EOLS | Beaver Sandra | CFO | A - Grant | $0.00 | +62.6K | 99.1K | +172% | $0 |
| D | 2023-01-27 | 2023-01-25 | EOLS | Avelar Rui | See Remarks | A - Grant | $0.00 | +97.6K | 350.8K | +39% | $0 |
| D | 2023-01-27 | 2023-01-25 | EOLS | MOATAZEDI DAVID | See Remarks, Dir | A - Grant | $0.00 | +187.9K | 679.9K | +38% | $0 |
| 2022-10-07 | 2022-10-06 | EOLS | Medytox Inc. | 10% | S - Sale | $8.99 | -38.3K | 7.26M | -0.5% | -$344.4K | |
| 2022-10-06 | 2022-10-05 | EOLS | Medytox Inc. | 10% | S - Sale | $8.95 | -6,848 | 7.30M | -0.1% | -$61.3K | |
| M | 2022-09-16 | 2022-09-14+ | EOLS | Medytox Inc. | 10% | S - Sale | $10.29 | -97.0K | 7.30M | -1% | -$997.9K |
| MI | 2022-09-13 | 2022-09-09+ | EOLS | HAYMAN ROBERT | Dir | P - Purchase | $10.40 | +10.0K | 8,909 | New | +$104.0K |
| A | 2022-09-13 | 2022-09-07 | EOLS | HAYMAN ROBERT | Dir | P - Purchase | $10.05 | +5,000 | 39.9K | +14% | +$50.2K |
| M | 2022-09-12 | 2022-09-08+ | EOLS | Medytox Inc. | 10% | S - Sale | $10.47 | -36.0K | 7.40M | -0.5% | -$376.9K |
| 2022-09-09 | 2022-09-07 | EOLS | HAYMAN ROBERT | Dir | P - Purchase | $10.05 | +4,967 | 39.8K | +14% | +$49.9K | |
| 2022-09-08 | 2022-09-06 | EOLS | BLANK SIMONE | Dir | P - Purchase | $9.24 | +20.0K | 54.9K | +57% | +$184.8K | |
| I | 2022-09-06 | 2022-09-06 | EOLS | FARRELL PETER C | Dir | P - Purchase | $9.10 | +10.0K | 10.0K | New | +$91.0K |
| D | 2022-09-06 | 2022-09-05 | EOLS | Beaver Sandra | CFO | A - Grant | $0.00 | +36.4K | 36.4K | New | $0 |
| 2022-08-03 | 2022-08-01 | EOLS | Medytox Inc. | 10% | S - Sale | $13.28 | -26.0K | 7.44M | -0.3% | -$345.3K | |
| M | 2022-05-18 | 2022-05-17+ | EOLS | SILVERNAIL LAUREN P | See Remarks | S - Sale | $12.78 | -68.2K | 141.6K | -33% | -$871.4K |
| 2022-05-18 | 2022-05-16 | EOLS | MOATAZEDI DAVID | See Remarks, Dir | S - Sale | $13.64 | -55.3K | 492.0K | -10% | -$754.6K | |
| M | 2022-05-17 | 2022-05-13+ | EOLS | GILL DAVID N | Dir | S - Sale | $13.35 | -10.3K | 34.6K | -23% | -$137.7K |
| 2022-03-30 | 2022-03-28 | EOLS | MOATAZEDI DAVID | See Remarks, Dir | S - Sale | $11.62 | -6,104 | 547.3K | -1% | -$70.9K | |
| 2022-03-10 | 2022-03-08 | EOLS | Muilenburg Crystal | CMO | S - Sale | $9.73 | -6,495 | 134.2K | -5% | -$63.2K | |
| 2022-03-10 | 2022-03-08 | EOLS | SILVERNAIL LAUREN P | See Remarks | S - Sale | $9.73 | -10.2K | 209.8K | -5% | -$99.2K | |
| 2022-03-10 | 2022-03-08 | EOLS | MOATAZEDI DAVID | See Remarks, Dir | S - Sale | $9.73 | -38.0K | 553.4K | -6% | -$369.5K | |
| 2022-03-10 | 2022-03-08 | EOLS | Avelar Rui | See Remarks | S - Sale | $9.73 | -10.2K | 253.2K | -4% | -$99.2K | |
| D | 2022-01-26 | 2022-01-24 | EOLS | GILL DAVID N | Dir | A - Grant | $0.00 | +15.6K | 39.9K | +64% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | SILVERNAIL LAUREN P | See Remarks | A - Grant | $0.00 | +53.6K | 220.0K | +32% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | Malik Vikram | Dir | A - Grant | $0.00 | +15.6K | 69.3K | +29% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | HAYMAN ROBERT | Dir | A - Grant | $0.00 | +15.6K | 34.9K | +81% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | Parschauer Karah Herdman | Dir | A - Grant | $0.00 | +15.6K | 34.9K | +81% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | Avelar Rui | See Remarks | A - Grant | $0.00 | +53.6K | 263.4K | +26% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | BLANK SIMONE | Dir | A - Grant | $0.00 | +15.6K | 34.9K | +81% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | MOATAZEDI DAVID | See Remarks, Dir | A - Grant | $0.00 | +214.3K | 591.4K | +57% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | Muilenburg Crystal | CMO | A - Grant | $0.00 | +50.0K | 140.7K | +55% | $0 |
| D | 2022-01-26 | 2022-01-24 | EOLS | FARRELL PETER C | Dir | A - Grant | $0.00 | +15.6K | 34.9K | +81% | $0 |
| 2022-01-07 | 2022-01-05 | EOLS | Stewart Brady | Dir | A - Grant | $0.00 | +36.5K | 36.5K | New | $0 | |
| 2021-09-07 | 2021-09-02 | EOLS | Alphaeon 1 LLC | 10% | S - Sale | $9.50 | -2.60M | 6.06M | -30% | -$24.68M | |
| 2021-08-31 | 2021-08-27 | EOLS | Medytox Inc. | 10% | P - Purchase | $10.93 | +51.0K | 7.46M | +0.7% | +$557.4K | |
| M | 2021-08-27 | 2021-08-25+ | EOLS | Medytox Inc. | 10% | P - Purchase | $11.06 | +110.0K | 7.41M | +2% | +$1.22M |
| M | 2021-08-25 | 2021-08-23+ | EOLS | Medytox Inc. | 10% | P - Purchase | $11.10 | +142.0K | 7.30M | +2% | +$1.58M |
| I | 2021-08-25 | 2021-08-23 | EOLS | Malik Vikram | Dir | S - Sale | $11.00 | -26.1K | 1.14M | -2% | -$286.8K |
| M | 2021-08-23 | 2021-08-19+ | EOLS | Medytox Inc. | 10% | P - Purchase | $10.53 | +103.0K | 7.11M | +1% | +$1.08M |
| MI | 2021-08-20 | 2021-08-19+ | EOLS | Malik Vikram | Dir | S - Sale | $10.59 | -61.8K | 1.17M | -5% | -$654.8K |
| M | 2021-08-19 | 2021-08-17+ | EOLS | Medytox Inc. | 10% | P - Purchase | $10.63 | +115.0K | 7.01M | +2% | +$1.22M |
| MI | 2021-08-19 | 2021-08-17+ | EOLS | Malik Vikram | Dir | S - Sale | $10.20 | -67.1K | 1.26M | -5% | -$684.4K |
| M | 2021-08-17 | 2021-08-13+ | EOLS | MOATAZEDI DAVID | See Remarks, Dir | S - Sale | $11.13 | -70.4K | 377.1K | -16% | -$783.9K |
| M | 2021-08-17 | 2021-08-13+ | EOLS | Medytox Inc. | 10% | P - Purchase | $11.18 | +114.7K | 6.88M | +2% | +$1.28M |
| M | 2021-08-13 | 2021-08-11+ | EOLS | Medytox Inc. | 10% | P - Purchase | $10.87 | +65.3K | 6.79M | +1.0% | +$709.4K |
| 2021-08-12 | 2021-08-10 | EOLS | SILVERNAIL LAUREN P | See Remarks | S - Sale | $11.18 | +14.3K | 195.0K | +8% | +$159.8K | |
| A | 2021-08-12 | 2021-08-10 | EOLS | MOATAZEDI DAVID | See Remarks, Dir | S - Sale | $11.18 | -41.8K | 447.5K | -9% | -$466.9K |
| A | 2021-08-12 | 2021-08-10 | EOLS | SILVERNAIL LAUREN P | See Remarks | S - Sale | $11.18 | -14.3K | 166.4K | -8% | -$159.8K |
| 2021-08-12 | 2021-08-10 | EOLS | Muilenburg Crystal | CMO | S - Sale | $11.18 | +5,362 | 101.5K | +6% | +$59.9K | |
| A | 2021-08-12 | 2021-08-10 | EOLS | Muilenburg Crystal | CMO | S - Sale | $11.18 | -5,362 | 90.7K | -6% | -$59.9K |
| 2021-08-12 | 2021-08-10 | EOLS | Avelar Rui | See Remarks | S - Sale | $11.18 | -14.3K | 209.8K | -6% | -$159.8K | |
| 2021-08-12 | 2021-08-10 | EOLS | MOATAZEDI DAVID | See Remarks, Dir | S - Sale | $11.18 | +41.8K | 531.0K | +9% | +$466.9K |
Purchase Sale Sale after option exercise All abbreviations